BARCLAYS PLC - KALA PHARMACEUTICALS INC ownership

KALA PHARMACEUTICALS INC's ticker is KALA and the CUSIP is 483119103. A total of 77 filers reported holding KALA PHARMACEUTICALS INC in Q1 2019. The put-call ratio across all filers is - and the average weighting 0.6%.

Quarter-by-quarter ownership
BARCLAYS PLC ownership history of KALA PHARMACEUTICALS INC
ValueSharesWeighting
Q1 2022$31,000
-82.4%
22,239
-84.8%
0.00%
Q4 2021$176,000
+100.0%
145,944
+328.6%
0.00%
Q3 2021$88,000
-29.6%
34,053
+43.3%
0.00%
Q2 2021$125,000
-69.0%
23,766
-60.3%
0.00%
Q1 2021$403,000
+358.0%
59,835
+361.1%
0.00%
Q4 2020$88,000
-59.6%
12,977
-54.8%
0.00%
Q3 2020$218,000
-87.0%
28,737
-82.0%
0.00%
-100.0%
Q2 2020$1,677,000
+1180.2%
159,593
+974.0%
0.00%
Q1 2020$131,000
+57.8%
14,860
-33.8%
0.00%
Q4 2019$83,000
+66.0%
22,436
+68.4%
0.00%
Q3 2019$50,000
-51.0%
13,323
-16.6%
0.00%
Q2 2019$102,000
+67.2%
15,974
+113.4%
0.00%
Q1 2019$61,000
+510.0%
7,485
+264.6%
0.00%
Q4 2018$10,000
-83.9%
2,053
-67.6%
0.00%
Q3 2018$62,000
-51.9%
6,342
-32.3%
0.00%
Q2 2018$129,000
+44.9%
9,361
+65.8%
0.00%
Q1 2018$89,000
+36.9%
5,646
+59.0%
0.00%
Q4 2017$65,000
-76.2%
3,551
-70.3%
0.00%
Q3 2017$273,00011,9490.00%
Other shareholders
KALA PHARMACEUTICALS INC shareholders Q1 2019
NameSharesValueWeighting ↓
Athyrium Capital Management, LP 1,333,333$5,073,000100.00%
CAXTON CORP 1,483,343$5,644,0006.36%
Polaris Venture Management Co. V, L.L.C. 1,197,032$4,555,0002.59%
RA Capital Management 4,537,478$17,265,0001.03%
Orbimed Advisors 3,447,840$13,119,0000.25%
Matisse Capital 46,500$177,0000.22%
PURA VIDA INVESTMENTS, LLC 332,831$1,266,0000.22%
Sofinnova Investments, Inc. 478,206$1,819,0000.16%
HARBOURVEST PARTNERS LLC 99,186$377,0000.16%
ALGERT GLOBAL LLC 47,195$180,0000.07%
View complete list of KALA PHARMACEUTICALS INC shareholders